Medicenna Therapeutics Corp(MDNAF)

Description: Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

---

Keywords: Cancer Disease Immunology Solid Tumors Antibodies Tumor Immunotherapy Treatment Of Cancer Autoimmune Disease Cancer Immunotherapy Immunotherapies Multiple Sclerosis Glioblastoma Brain Tumor Cytokine Host Disease Recurrent Glioblastoma Interleukins

---

Home Page: www.medicenna.com

2 Bloor Street West
Toronto, ON M4W 3E2
Canada
Phone: 416 648 5555

---

Officers

Exchange: OTCQX

Country: US : United States of America

Currency: US Dollar ($)